ctrl K

Watchlist Price Alert

Neurogene Inc. (NGNE)

NASDAQ: NGNE · Real-Time Price · USD

16.66

-0.22 (-1.30%)

At close: Jun 26, 2025, 2:00 PM

-1.30% (1D)

Bid	16.59
Market Cap	237.61M
Revenue (ttm)	925K
Net Income (ttm)	-80.87M
EPS (ttm)	-4.36
PE Ratio (ttm)	-3.82
Forward PE	-3.4
Analyst	Buy

Ask	16.75
Volume	61,950
Avg. Volume (20D)	261,427
Open	17.26
Previous Close	16.88
Day's Range	16.26 - 17.26
52-Week Range	6.88 - 74.49
Beta	1.58

About NGNE

undefined

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol NGNE

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for NGNE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

-7.12%

Neurogene shares are trading lower after Baird dow... Unlock content with Pro Subscription

7 months ago

-42.58%

Neurgogene shares are trading lower after the company announced it brought its high-dose gene therapy trial to a halt after a serious adverse event in a Rett syndrome patient.

News

news image

2 weeks ago · businesswire.com

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...

news image

1 month ago · businesswire.com

Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...

news image

1 month ago · businesswire.com

Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...

news image

1 month ago · businesswire.com

Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...

news image

2 months ago · businesswire.com

Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...